ArticleFrontiers in immunology2025
A case report of advanced pancreatic neuroendocrine carcinoma with Ki67 80%, CPS 0, and pMMR achieving durable complete response for over 7 years after combination immunotherapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival.Frontiers in immunology · 2026Article
- Beyond combination: sequencing priming modalities before immune checkpoint inhibitors to convert immunologically cold tumors toward an ICI-responsive phenotype.Frontiers in immunology · 2026Review
- Complete response to BRICS in Locally advanced pancreatic cancer (pMMR, CPS 30): a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic neuroendocrine carcinoma (pNEC) is a rare and aggressive malignancy. For patients with metastatic pNEC, the response to first-line chemotherapy remains unfavorable, with a median overall survival of less than one year. Furthermore, there are no standard-of-care therapeutic options following disease progression, representing a significant unmet clinical need. Case presentation: This is a case report of a patient diagnosed with metastatic pNEC presenting with upper abdominal pain, testing 80% positive for the Ki67 marker, a combined positive score (CPS) of 0, and proficient mismatch repair (pMMR). Following progression after chemotherapy, the patient received combination immunotherapy, involving multi-site, multi-dose, and multi-type radiotherapies combined with programmed death 1 (PD-1), accompanied by continuous probiotic supplementation. Imaging examination revealed that the tumor completely disappeared, and the patient maintained a no-evidence-of-disease (NED) status for over seven years. Conclusion: This case demonstrates that multi-site, multi-dose, and multi-type radiotherapies can more effectively reveal the heterogeneous tumor antigens, and the combined therapy of immunotherapy and probiotics may achieve sustained immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.